NSCLC Drug Development Strapline

Advance Cutting-Edge Research and Development with Next-Generation Targeted & Immune Therapies (mono & combination) and Learn How to Best Utilize them with Precision Oncology

The Non-Small Cell Lung Cancer (NSCLC) Drug Development Summit is the definitive industry-led forum for drug development in the largest solid tumor indication.

Arriving at a critical point for the NSCLC drug development field, as checkpoint inhibitors are on the brink of entering the perioperative setting and the targeted space is rapidly expanding, this forum will enable you to see a full picture of the developmental landscape and identify what MoAs and targets future biopharma investment will be put towards.

Network with 80+ expert drug developers over 3-days of comprehensive insights to uncover the latest industry knowledge on the molecular heterogeneity of lung cancer, the implications for therapeutic design when considering acquired resistance and optimal application of new drugs in the clinic.

View the event guide now to learn more!

The Excitement is Building:

"The Non-Small Cell Lung Cancer Summit will be an important venue to learn more about the latest developments in lung cancer, including the emerging new treatments, and some of the informative new science."

Tony Jarkowski, Development Lead, Bristol-Myers Squibb


"The summit is an excellent lineup of talks and speakers. There have been rapid practice changing advances in NSCLC and the summit is a great way to stay abreast of the progress and cutting-edge science."

Kelly Covello, PHD, Head of Medical Affairs, Mirati Therapeutics Inc.

Expert Speaker Faculty Includes:

What Will You Learn?

NSCLC Favicon

Knowledge gained from the current EGFR-TKI successes and implementing it into strategies for improvement, best application strategies and potential combination partners with AstraZeneca, Puma Biotechnology, Cullinan Oncology and Takeda

NSCLC Favicon

The potentials of targeting currently untreatable acquired resistances through small molecules and biologics to develop novel agents against mutations with AbbVie, Merus, Black Diamond, AOM Biosciences and Mirati Therapeutics.

NSCLC Favicon

The exciting advancements in the NSCLC rare mutations space, with the novel therapies in targeting BRAF, NGR1 fusions and HER2 with Kinnate Biopharmaceuticals, Elevation Oncology and Boeringer Ingelheim.

NSCLC Favicon

The power of the immune system to treat NSCLC by delving into the current best, novel targets and combination strategies to improve patent outlook with Merck & Co, Immutep, BerGenBio and Bristol-Myers Squibb.

NSCLC Favicon

The efficacy of companion diagnostics and look to the future of early disease detection, application and differences in patient populations and how combination therapy can best be exploited to beat this drastically unmet clinical need with UAMS, Takeda, Novartis, BloodPAC and Amgen.

Who Will You Meet?

NSCLC Whos Attending

Proud to Partner With:

Media Partners: